Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SAN RAMON, Calif., Sept. 20, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer, will present at the Annual Ladenburg Thalmann Healthcare Conference, being held on September 27, 2016 at The Sofitel, in New York City. During the presentation, Mr. Rigby will provide an overview and update on the company's business.
Date: Tuesday, September 27, 2016
Time: 9:30 AM ET
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group David Burke (646) 536-7009 [email protected]
